[ Skip to Main Content ]
COVID-19: How We’re Responding

Our Work

This #GivingTuesday, make a real difference for women, girls, and families, and support EngenderHealth’s mission to advance gender equality in and through sexual and reproductive health and rights.

Now through Dec 1, all donations will be MATCHED! http://bit.ly/GivingTuesEH

🚨2 DAYS LEFT🚨

To make a matched donation supporting increased access to #reprohealth and contraceptive services, gender-based violence prevention, and the advancement of gender equality. #GivingTuesday http://bit.ly/GivingTuesEH

#BitcoinTuesday @TheGivingBlock @GivingTuesday

Between now and #GivingTuesday on Dec 1, we hope you keep women and girls a priority in your giving. Your support of EngenderHealth enables more women to have the knowledge and healthcare they need to transform their lives.

Make a matched donation today: http://bit.ly/GivingTuesEH

#GivingTuesday is Dec 1, but our matched donation opportunity has already started!

Help us reach our #GivingTuesday goal of raising $17,000 to increase access to #reprohealth & #contraception, prevent gender-based violence, and increase gender equality. http://bit.ly/GivingTuesEH

🚨3 DAYS LEFT🚨

To make a matched donation supporting life-saving sexual and reproductive health services for people around the world. #GivingTuesday

Visit http://bit.ly/GivingTuesEH or text Engender to 41444 to donate!

#BitcoinTuesday @TheGivingBlock

➡️Hand-washing stations built
➡️Masks distributed
➡️Contraceptive services continued
➡️Maternal health improved

EngenderHealth does this work & so much more during #COVID19. Consider supporting us today – now through Dec 1, all donations will be matched. http://bit.ly/GivingTuesEH

With our support, government #COVID19 task forces have paid attention to sexual & #reprohealth, & providers are continuing to offer services.

With your support, we can continue this work. Through #GivingTuesday, all donations are matched. @GivingTuesday

http://bit.ly/GivingTuesEH

🚨4 DAYS LEFT🚨

To make a matched donation for #GivingTuesday.

Together, we can make an impact on women, girls, and communities worldwide.

Visit http://bit.ly/GivingTuesEH or text Engender to 41444 to donate!

#BitcoinTuesday @GivingTuesday @TheGivingBlock

In the spirit of giving thanks, and with #GivingTuesday in 5 days, we hope you consider making a matched donation to support us as we work for access to high-quality healthcare, #contraception, and economic empowerment.

Give today: http://bit.ly/GivingTuesEH

#BitcoinTuesday

#TanzaniaHealthSummit attendees: Today, there will be an exciting session on #youth capacity building & result-based approaches to fill the gaps & curb the challenges that youth face. Speakers include our #Tanzania Knowledge Management Officer, @RehemaGeorge7. Join in! #THS2020

Load More...

Eclampsia and Pre-Eclampsia

Giving birth should be a time for celebration, but for more than half a million women each year—one every 90 seconds—pregnancy and childbirth end in death and mourning. Ninety-nine percent of these deaths occur in developing countries, and nearly all are preventable.

One of the leading causes of maternal death is pre-eclampsia—the rapid elevation of blood pressure during pregnancy—which, if untreated, can lead to seizures (eclampsia), kidney and liver damage, and ultimately, death. Eclampsia and severe pre-eclampsia claim the lives of an estimated 63,000 women each year, as well as the lives of many of their babies.  

A Ready Solution
The World Health Organization recognizes and recommends injectable magnesium sulfate—also known as Epsom salts—as the safest, most effective, and lowest-cost medication for treating pre-eclampsia and eclampsia. Magnesium sulfate is the standard treatment for these conditions in the developed world and has been for 20 years. Less-effective and riskier medications (such as diazepam and phenytoin), however, are still widely used in developing countries—if any treatment is available at all.

 

OUR COMMITMENT
We commit to reducing maternal mortality with magnesium sulfate in India, Mexico, and Nigeria. Through training, advocacy, and education, we will increase access to the lifesaving treatment for pre-eclampsia and eclampsia, leading causes of maternal mortality.

 

 

Clinton Global Initiative Commitment
This disparity must end. EngenderHealth, the University of Oxford, and the John D. & Catherine T. MacArthur Foundation are making a joint commitment as part of the Clinton Global Initiative to expand access to magnesium sulfate by:

  • Training health professionals through web-based interactive programs on when and how to administer magnesium sulfate
  • Advocating for magnesium sulfate to be part of every developing country’s list of essential drugs
  • Helping develop and/or reinforce national protocols mandating magnesium sulfate as the preferred treatment for pre-eclampsia and eclampsia
  • Ensuring the availability of magnesium sulfate in hospitals

Call to Action
In 2007, EngenderHealth and the University of Oxford brought together leading scientists, advocates, researchers, and representatives of the WHO, UNICEF, United Nations agencies, and national ministries of health from around the world to identify barriers to the availability and use of magnesium sulfate to treat pre-eclampsia and eclampsia. This historic gathering of global public health experts identified the primary barriers to be a lack of national guidelines, a shortage of educated and trained health care professionals, and scarce supplies of magnesium sulfate.

Based on these conclusions, EngenderHealth and the University of Oxford developed a “Call to Action” and report that called on policy makers and ministers of health to make pre-eclampsia and eclampsia a higher priority and to set national guidelines for treatment and care based on WHO guidelines. Decision makers and international and national health organizations and agencies were also urged to help make magnesium sulfate more available and affordable.

The full report, Balancing the Scales: Expanding Treatment for Pregnant Women with Life-Threatening Hypertensive Conditions in Developing Countries, is available for download (PDF, 316KB), as is the International Call to Action (PDF, 27KB).

Share this page: